Literature DB >> 34053056

Methods to Study Posttranslational Modification Patterns in Cytotoxic T-Cells and Cancer.

Annamaria Deleonardis1,2, Massimo Papale3.   

Abstract

Protein posttranslational modifications (PTMs) regulate intracellular signaling associated with development and progression of many diseases; thus, they are key to understanding pathological mechanisms and set up more tailored therapies. In addition, many posttranslationally modified proteins are released into biological fluids and can be used as new and more specific biomarkers. Based on this evidence, we analyzed the role of some PTMs in cancer and described the correlation between specific PTMs and T-cells activation/inhibition in cancer microenvironment. In the second part of this chapter, we analyzed the most commonly used approaches for qualitative and quantitative determination of PTMs. The comparison of three distinct but often complementary methodologies such as immunoblotting, mass spectrometry, and ELISA assays has allowed to highlight the pros and cons of each approach with a focus on their current application and their future developments to obtain more confident biomarkers and therapeutic targets useful for diagnosis, prognosis, and monitoring of the response to therapy.

Entities:  

Keywords:  Biomarkers; Cancer; ELISA; Immunoblotting; Mass Spectrometry; PTMs; Phospho-ELISA; Posttranslational Modifications; T-Cells

Year:  2021        PMID: 34053056     DOI: 10.1007/978-1-0716-1507-2_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  61 in total

Review 1.  Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry.

Authors:  Ole Nørregaard Jensen
Journal:  Curr Opin Chem Biol       Date:  2004-02       Impact factor: 8.822

Review 2.  Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics.

Authors:  Karl E Krueger; Sudhir Srivastava
Journal:  Mol Cell Proteomics       Date:  2006-07-14       Impact factor: 5.911

3.  Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer.

Authors:  Caterina Cinti; Marcella Macaluso; Antonio Giordano
Journal:  Oncogene       Date:  2005-09-01       Impact factor: 9.867

Review 4.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

5.  Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation.

Authors:  Gregory L Baker; Mark W Landis; Philip W Hinds
Journal:  Cell Cycle       Date:  2005-02-21       Impact factor: 4.534

Review 6.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

7.  Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein.

Authors:  Fumiaki Okahara; Hideki Ikawa; Yasunori Kanaho; Tomohiko Maehama
Journal:  J Biol Chem       Date:  2004-09-07       Impact factor: 5.157

Review 8.  PTEN function: how normal cells control it and tumour cells lose it.

Authors:  Nick R Leslie; C Peter Downes
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 9.  Role of the retinoblastoma protein in the pathogenesis of human cancer.

Authors:  W R Sellers; W G Kaelin
Journal:  J Clin Oncol       Date:  1997-11       Impact factor: 44.544

10.  Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer.

Authors:  Sunanda J Chatterjee; Ben George; Peter J Goebell; Mohammad Alavi-Tafreshi; Shan-Rong Shi; Yuen Kai Fung; Peter A Jones; Carlos Cordon-Cardo; Ram H Datar; Richard J Cote
Journal:  J Pathol       Date:  2004-07       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.